Gossamer Bio Announces Clinical Trial Collaboration Agreement With Merck to Evaluate GB1275 in Combi
Phase 1/2 trial ongoing with multiple patients dosed in GB1275 monotherapy dose escalation – GB1275 granted Orphan Drug Designation for the treatment of pancreatic cancer by the U.S. Food and Drug Administration – Preclinical data for GB1275 featured as cover article in July 3rd edition of Science Translational Medicine – SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq:GOSS), a clinical-stage biopharmaceutical company, today announced that it has entered into a clinica